S80088
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/5/15 21:17:34
- 訪問次數(shù) 199
聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息，謝謝!
- 提示：詳情請(qǐng)下載說明書。
- 產(chǎn)品描述： CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively.
- 靶點(diǎn)： Aurora A:15 nM (IC50);Aurora B:25 nM (IC50);Aurora C:19 nM (IC50)
- 體內(nèi)研究： CCT 137690 slows the growth of the SW620 xenografts with no observed toxicity. CCT 137690 significantly inhibits tumour growth in a transgenic mouse model of neuroblastoma (TH-MYCN) that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation
- 參考文獻(xiàn)：
1. Bavetsias V, et al. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem. 2010 Jul 22;53(14):5213-28. 2. Faisal A, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011 Nov;10(11):2115-23.
- 溶解度： Soluble in DMSO
- 保存條件： 2-8℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 1.813 ml 9.067 ml 18.133 ml 5 mM 0.363 ml 1.813 ml 3.627 ml 10 mM 0.181 ml 0.907 ml 1.813 ml 50 mM 0.036 ml 0.181 ml 0.363 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性，僅供客戶參考交流研究之用。
采購(gòu)中心
化工儀器網(wǎng)